Yizhi Jiang

Yizhi Jiang


Research Focus & Metrics

Academic Career Length

5Years (2022-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
23 September 2024 in British Journal of Haematology
Verified
Journal Article
Closed access
YJYizhi Jiang
Yizhi Jiang
JLJizhe Li
Jizhe Li
JHJun Huang
Jun Huang
ZZZichan Zhang
Zichan Zhang
XLXiaocen Liu
Xiaocen Liu
LZLu Zhou
Lu Zhou

7 December 2022 in Hematology
Verified
Journal Article
Open access
YJYizhi Jiang
Yizhi Jiang
ZWZhong-Ling Wei
Zhong-Ling Wei
NWNa-Na Wang
Na-Na Wang
CHChen Huang
Chen Huang
JHJun Huang
Jun Huang
DHDongping Huang
Dongping Huang
Background: The V617F mutation of Janus-associated kinase 2 (JAK2) is common in myeloproliferative neoplasms (MPN). JAK2 V617F mutation can be detected in patients with de novo acute myeloid leukemia (AML), but de novo acute promyelocytic leukemia (APL) with JAK2 V617F mutation is rare. Case presentation: We report a case of APL with both the t(15;17) translocation as well as the JAK2 V617F mutation that transformed into MPN (PV/ET). Conclusions: A de novo APL patient presented initially with JAK2 V617F. After ATRA and ATO dual induction and chemotherapy consolidation, the patient achieved complete remission (CR) with undetectable PML/RAR alpha. However, the JAK2 V617F remained positive, and the patient developed MPN (PV/ET) 22 months later, which responded well to interferon therapy. AML, acute myeloid leukemia; APL, acute promyelocytic leukemia; ATRA, all-trans retinoic acid; ATO, arsenic trioxide; BM, bone marrow; CR, complete remission; ET, essential thrombocythemia; Hb, hemoglobin; JAK2, Janus-associated kinase 2; MPN, myeloproliferative neoplasms; PLT, platelets; PMF, primary myelofibrosis; PML/RAR alpha; PV, polycythemia vera; WBC, white blood cells.

5 August 2025 in Thrombosis Research
Verified
Journal Article
Closed access
TLTianyi Li
Tianyi Li
DHDongping Huang
Dongping Huang
YJYizhi Jiang
Yizhi Jiang

1 July 2024
Verified
Journal Article
Closed access
JLJizhe Li
Jizhe Li
NWNana Wang
Nana Wang
CHChen Huang
Chen Huang
YJYizhi Jiang
Yizhi Jiang
DHDongping Huang
Dongping Huang

13 November 2025 in Cancer Letters
Verified
Journal Article
Open access
YJYizhi Jiang
Yizhi Jiang
FLFeng Liu
Feng Liu
YYYuqiong Yang
Yuqiong Yang
JHJun Huang
Jun Huang
JLJizhe Li
Jizhe Li
DHDongping Huang
Dongping Huang
Genomic analyses have revolutionized risk stratification and clinical management of pediatric B-cell acute lymphoblastic leukemia (B-ALL), but these methods are time-consuming and costly. To address this gap, we employed highly sensitive and specific Olink proteomics analysis of bone marrow plasma samples from pediatric B-ALL patients and B-ALL patients with complete molecular remission (CMR) as controls. Fifty pediatric B-ALL patients and 43 controls were randomly divided into a "discovery" cohort (30 B-ALL patients, 26 CMR controls), and a "validation" cohort (20 B-ALL patients and 17 CMR controls). The Olink Target 96 Oncology Response protein panel was used. Normalized log2-scale protein expression values revealed 37 differentially expressed proteins (DEPs) between pediatric B-ALL and CMR control groups. LASSO regression analysis showed nine of these DEPs, including CXCL13, NCR1, ADA, IL6, HO-1, CCL3, CCL4, CD27, and ADGRG1, to be significant in differentiating between patients with B-ALL and CMR controls (validation AUC = 0.98). We further strengthened the study by validating key Olink-identified proteins using independent assays, including ELISA in patient bone marrow plasma and immunohistochemistry in patient-derived xenograft tissues, which confirmed some Olink proteomic findings, such as CCL3, CCL4, and CD27. In addition, we found that higher levels of DEPs, such as CD27, TNF, CCL3, CCL4, IL12RB1, PDCD1, and GZMB, in patients with genetic alterations associated with poor prognosis. Our Olink proteomics analysis identified nine key proteins that were differentially expressed between the pediatric B-ALL and control groups, which may contribute to the diagnosis and/or risk stratification of pediatric B-ALL.

1 December 2025 in Research Square
Verified
Preprint
Open access
PDF file
APAnqi Peng
Anqi Peng
LJLi Jizhe
Li Jizhe
JHJun Huang
Jun Huang
YYYuqiong Yang
Yuqiong Yang
YJYizhi Jiang
Yizhi Jiang
DHDongping Huang
Dongping Huang
Background: The neutrophil percentage-to-albumin ratio (NPAR) is an emerging indicator of inflammation that has been associated with the prognosis of various diseases, including hypertension, diabetes, and cardiovascular disease. NPAR is calculated by multiplying the neutrophil percentage by 100 and dividing it by the albumin value. This study aimed to evaluate the predictive value of NPAR for all-cause mortality in anemic patients. We employed Kaplan–Meier analysis, multiple regression models, restricted cubic splines (RCS), and threshold effect analysis to explore these associations. Methods: This study included 3,258 anemic individuals. The relationship between NPAR and all-cause mortality was evaluated using Kaplan–Meier analysis and multiple regression models. RCS curves were employed to assess potential nonlinear relationships, while threshold effect analysis was used to identify breakpoints in the association between NPAR and mortality risk. Subgroup analyses were conducted to examine variations in this relationship across different population strata. Results: The study population included 3,258 anemic patients, with a mean follow-up period of 94.3 months. During follow-up, 904 participants (27.75%) died. Kaplan–Meier analysis revealed that individuals in the highest NPAR quartile (Q4) exhibited significantly higher cumulative mortality compared with those in the lowest quartile (Q1) (p < 0.001). Multiple regression analysis showed that, in fully adjusted models, each unit increase in NPAR among individuals in the highest quartile was associated with a 65.4% increased risk of all-cause mortality. RCS and threshold effect analyses revealed a nonlinear relationship between NPAR and mortality, with a breakpoint at NPAR = 15.116. Below this threshold, no statistical association was observed, while above the threshold, NPAR was positively associated with increased mortality risk. Subgroup analyses demonstrated that the association between NPAR and mortality was particularly significant in individuals aged < 60 years and those with a body mass index (BMI) ≥ 30 kg/m². Conclusions: Our findings indicate that elevated NPAR is independently associated with increased all-cause mortality in anemic individuals. The nonlinear relationship and identified breakpoint suggest that NPAR may serve as a valuable prognostic biomarker for mortality risk in this population. Further research should focus on the clinical utility of NPAR in guiding therapeutic interventions for anemia.